# Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the Transition Policy

Phases II, III, and IV



# **Guiding Principles**

- Focus on commitments:
  - Standardizing benefits through a single delivery system
  - Improving access through a broad pharmacy network
  - Applying statewide utilization management protocols
  - Strengthening California's ability to negotiate supplemental drug rebates
- Drive to program goals through partnership:
  - Advocates
  - Associations
  - Pharmacies
  - Prescribers

# **Approach to Reinstatement**

- Phased, iterative approach, informed by:
  - **≻** Data
  - Lessons Learned
  - ➤ Stakeholder feedback
  - > Learnings from each prior phase
- Align with objectives to reduce disruption and ensure safe and timely delivery of pharmacy benefits
- Commitment to 30-day advance notice for PA reinstatement and 90-day notice for retirement of Transition Policy

#### Phase 1

- » Implementation of safety claims edits July 22
- » Reinstated PA requirements for new start prescriptions in 11 standard therapeutic drug classes September 16
- » Excluded new start prescriptions for beneficiaries 21 years of age and younger

#### **Current State**

As of December 5, Medi-Cal Rx had

- » Processed over 116 million point-of-sale pharmacy paid claims to participating pharmacies totaling approximately \$14.6 billion in payments
- » Processed more than 273,000 prior authorization requests

# Phase II: Reinstate PAs for Remaining STCs

30 Day Advance Notice



## Phase II

Wave 1: January 20, 2023

**39 STCs** 

**New Starts only** 

Wave 2: February 24, 2023

**Remaining STCs** 

Beneficiaries 22 and older

## **Phase III: Retire Transition Policy**

90 Day Advance Notice for Phase III

### Phase II

#### Phase III

**Transition Lifts: March 24, 2023 – June 23, 2023** 

Beneficiaries 22 and older

#### **Transition**

Lift: Removal of the Transition Policy for identified STCs.

# Phase IV: Reinstate PAs for <21 Population; Enteral Nutrition Products (all ages)

90 Day Advance Notice for Phase IV

Phase II

Phase III

Phase IV

No sooner than July

Beneficiaries 22 and older

# **Resources and Support**

Medi-Cal Rx will provide resources to support pharmacies and prescribers

- » Reinstatement-focused tab on Medi-Cal Rx website with links to:
  - » Alerts and Weekly Newsletters
  - » Frequently Asked Questions (FAQs)
  - » Monthly Updated Medi-Cal Approved NDC List
- » Weekly Office hours
- » Medi-Cal Rx Customer Service Center at 1-800-977-2273, 24 hours/7 days, 365 days per year.
- » Providers can also seek assistance via the Education and Outreach team at MediCalRxEducationOutreach@magellanhealth.com



# Questions

# We thank you for your continued partnership and commitment to serving beneficiaries enrolled with Medi-Cal

# **APPENDIX**

# P2W1 STCs (39)

STC	STC Description
95	ALL OTHER DERMATOLOGICALS
59	ANABOLICS
60	ANDROGENS
45	ANESTHETIC LOCAL TOPICAL
42	ANTIARTHRITICS
94	ANTIFUNGALS
32	ANTIMALARIALS
31	ANTIPARASITICS
09	ANTIPARKINSON
01	ANTI-ULCER PREPS/GASTROINTESTINAL PREPS
33	ANTIVIRALS
90	BIOLOGICALS
26	CEPHALOSPORINS
50	CORTICOTROPINS
93	EMOLLIENTS PROTECTIVES
25	ERYTHROMYCINS
61	ESTROGENS
80	FAT SOLUBLE VITAMINS
83	FOLIC ACID PREPARATIONS

STC	STC Description
38	GENERAL ANTIBACTERIALS AND ANTISEPTICS
51	GLUCOCORTICOIDS
57	IODINE THERAPY
82	MULTIVITAMINS
08	MUSCLE RELAXANTS
41	NON-OPIOID ANALGESICS
20	OPHTHALMIC PREPARATIONS
27	OTHER ANTIBIOTICS
64	OTHER HORMONES
22	PENICILLINS
62	PROGESTERONE
23	STREPTOMYCINS
24	SULFONAMIDES
63	SYSTEMIC CONTRACEPTIVES
34	TB PREPARATIONS
21	TETRACYCLINES
55	THYROID PREPS
19	TOPICAL NASAL AND OTIC PREPARATIONS
28	URINARY ANTIBACTERIALS
85	VITAMIN K